MDT

100.71

0%↓

135.72

-0.01%↓

VEEV

217.61

-2.73%↓

HQY

82.76

-2.65%↓

NEOG

10.24

+2.4%↑

MDT

100.71

0%↓

135.72

-0.01%↓

VEEV

217.61

-2.73%↓

HQY

82.76

-2.65%↓

NEOG

10.24

+2.4%↑

MDT

100.71

0%↓

135.72

-0.01%↓

VEEV

217.61

-2.73%↓

HQY

82.76

-2.65%↓

NEOG

10.24

+2.4%↑

MDT

100.71

0%↓

135.72

-0.01%↓

VEEV

217.61

-2.73%↓

HQY

82.76

-2.65%↓

NEOG

10.24

+2.4%↑

MDT

100.71

0%↓

135.72

-0.01%↓

VEEV

217.61

-2.73%↓

HQY

82.76

-2.65%↓

NEOG

10.24

+2.4%↑

Strona główna・Stock List・Madrigal Pharmaceuticals Inc

Madrigal Pharmaceuticals Inc

Closed

SectorHealthcare

498.69 -0.01

Buy Sell

Overview

Share price change

24h

Current

Min

484.77

Max

500

Key metrics
By Trading Economics
Income	-72M -114M
Sales	74M 287M
Profit margin	-39.75
Employees	528
EBITDA	-68M -106M

Recommendations
By TipRanks
Recommendations	Strong Buy
12 Months Forecast	+32.31% upside

Dividends
By Dow Jones
Next Earnings	25 lut 2026

Market Stats
By TradingEconomics
Market Cap	2.1B 11B
Previous open	498.7
Previous close	498.69

News Sentiment

By Acuity

28%

72%

67 / 352 Ranking in Healthcare

Technical Score

By Trading Central

Confidence

Very Strong Bearish Evidence

263.2 / 277.1 Support & Resistance

Madrigal Pharmaceuticals Inc Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

27 sty 2026, 23:07 UTC

Earnings

Texas Instruments Says Data Centers, Industrial Recovery Driving Growth into 1Q -- Update

27 sty 2026, 21:27 UTC

Earnings

Texas Instruments 4Q Sales Rise, Profit Falls

27 sty 2026, 23:55 UTC

Market Talk

Yen Weakens Slightly on Possible Technical Correction -- Market Talk

27 sty 2026, 23:47 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

27 sty 2026, 23:47 UTC

Market Talk

Nikkei May Decline Amid Caution Over Earnings -- Market Talk

27 sty 2026, 23:39 UTC

Market Talk

Gold Falls on Likely Technical Correction, Possible Profit-Taking -- Market Talk

27 sty 2026, 23:20 UTC

Earnings

SK Innovation: Asset-Impairment Losses Weighed on Earnings

27 sty 2026, 23:20 UTC

Earnings

SK Innovation: Industry Downturn, Narrower Profit Margins Weighed on Earnings

27 sty 2026, 23:19 UTC

Earnings

SK Innovation Posts Net Loss for Second Consecutive Year

27 sty 2026, 23:19 UTC

Earnings

SK Innovation 2025 Loss KRW5.406T Vs. Loss KRW2.372T >096770.SE

27 sty 2026, 23:18 UTC

Earnings

SK Innovation 2025 Oper Pft KRW448.07B Vs. Pft KRW356.07B >096770.SE

27 sty 2026, 23:18 UTC

Earnings

SK Innovation 2025 Rev KRW80.296T Vs. KRW74.243T >096770.SE

27 sty 2026, 23:11 UTC

Market Talk

Global Equities Roundup: Market Talk

27 sty 2026, 23:11 UTC

Market Talk

Alkane Resources Bull Positive on Outlook in Red-Hot Gold Market -- Market Talk

27 sty 2026, 23:07 UTC

Market Talk

Acquisitions, Mergers, Takeovers

Freightways's Australian M&A Adds Ballast to Bull's View -- Market Talk

27 sty 2026, 22:17 UTC

Market Talk

U.S. Dollar Slips Following Trump Comments -- Market Talk

27 sty 2026, 22:06 UTC

Earnings

Boeing's Stepped-Up Plane Deliveries Lift Sales -- Update

27 sty 2026, 21:51 UTC

Earnings

Texas Instruments Stock Jumps on Strong Outlook -- Barrons.com

27 sty 2026, 21:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

27 sty 2026, 21:43 UTC

Earnings

RTX Stock Jumps After Earnings. It Has 'Great Momentum,' Says CEO. -- Barrons.com

27 sty 2026, 21:41 UTC

Earnings

GM Lost Billions on EVs, Still Beat Wall Street's Expectations -- 5th Update

27 sty 2026, 21:38 UTC

Earnings

These Stocks Are Today's Movers: UnitedHealth, Humana, Micron, Corning, CoreWeave, UPS, GM, and More -- Barrons.com

27 sty 2026, 21:32 UTC

Earnings

Ampol: Modest Profit From F&I International in 2025

27 sty 2026, 21:32 UTC

Earnings

Ampol: F&I Australia Ebit Up by High Single Digit Percent in 2025

27 sty 2026, 21:31 UTC

Earnings

Ampol: New Zealand Ebit in 2025 In Line With Prior Year

27 sty 2026, 21:31 UTC

Earnings

Ampol: Australia Convenience Retail Ebit Up Mid-Single Digit Percent in 2025

27 sty 2026, 21:30 UTC

Earnings

Ampol 4Q Lytton Refinery Production 1.56 Billion Liters

27 sty 2026, 21:29 UTC

Earnings

Ampol FY Unaudited Replacement-Cost Ebitda A$1.44 Billion

27 sty 2026, 21:29 UTC

Earnings

Ampol FY Unaudited Replacement-Cost Operating Profit A$945 Million

27 sty 2026, 21:28 UTC

Earnings

Ampol 4Q Lytton Refiner Margin US$15.14/Bbl

Peer Comparison

Price change

Madrigal Pharmaceuticals Inc Forecast

Price Target

By TipRanks

32.31% upside

12 Months Forecast

Average 660.44 USD 32.31%

High 900 USD

Low 533 USD

Based on 12 Wall Street analysts offering 12 month price targets forMadrigal Pharmaceuticals Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

12 ratings

Buy

Hold

Sell

Based on 12 analysts giving stock ratings to Madrigal Pharmaceuticals Inc - Dist in the past 3 months.

Technical Score

By Trading Central

263.2 / 277.1Support & Resistance

Bearish events outweigh bullish events.

Recent bearish events outweigh bullish events.

The bullish and bearish events are balanced.

Sentiment

By Acuity

67 / 352 Ranking in Healthcare

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Madrigal Pharmaceuticals Inc

Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) in the United States. Its lead product candidate is resmetirom, a liver-directed thyroid hormone receptor beta agonist, which is in Phase 3 clinical trials for treating NASH. The company is headquartered in West Conshohocken, Pennsylvania.